ICRT14 is a small-molecule inhibitor investigated primarily in oncology research for its potential to block Wnt/beta-catenin signaling pathways involved in tumor cell proliferation. As a potent antagonist… Read more
ICRT14 is a small-molecule inhibitor investigated primarily in oncology research for its potential to block Wnt/beta-catenin signaling pathways involved in tumor cell proliferation. As a potent antagonist utilized in drug discovery and targeted therapy development, it serves as a critical subject for pharmacological study. This category includes the parent compound alongside its deuterated form, ICRT-14-d5, which is highly valued as a stable isotope labelled internal standard. Laboratories rely on these high-quality reference standards for precise quantitative analysis, impurity profiling, and metabolic studies using mass spectrometry. By providing essential materials for method validation and bioanalytical assay development, these compounds support rigorous quality control in preclinical and clinical research settings, ensuring accurate monitoring of kinase inhibition activity and drug performance during complex investigative processes.